In last few decades, risk-adapted therapy has achieved cure rates exceeding 85% in pediatric patients and 40–60% in adults, however, certain subtypes such as KMT2A-rearranged, BCR::ABL1-positive (Ph +), BCR::ABL1-like (Ph-like), hypodiploid, iAMP21, and IKZF1-deleted B-ALL, remain associated with poor prognosis, treatment resistance, and higher relapse rates [4–10]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.